In December 2024, we entered into an option-type drug discovery collaboration agreement with Congruence, utilizing their proprietary Revenir™ drug discovery platform to generate small molecule drug candidates in the field of oncology. The new agreement aims to create small molecule modulators in therapeutic areas distinct from the previous agreement. As with the prior agreement, under this new collaboration, Congruence will generate small molecule drug candidates targeting different proteins in the areas of neurology and immunology, respectively. Ono will obtain exclusive worldwide option rights to develop, manufacture and commercialize the selected small molecule drug candidates generated by Congruence. Under the terms of this agreement, Ono will pay Congruence an upfront payment, research funding, and milestone payments based on research, development and commercialization progress, as well as tiered royalties on net sales after product launch.